Esperion Therapeutics Inc(0ET)

Description: Esperion Therapeutics, Inc., a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol (LDL-C). Its marketed products include NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets that are oral, once-daily, non-statin medicines for the treatment of primary hyperlipidemia in adults with heterozygous familial hypercholesterolemia or atherosclerotic cardiovascular disease who require additional lowering of LDL-C. The company's products also include NILEMDO, an ATP Citrate Lyase (ACL) inhibitor that lowers LDL-C and cardiovascular risk by reducing cholesterol biosynthesis and up-regulating the LDL receptors; and NUSTENDI, a bempedoic acid and ezetimibe tablet to treat elevated LDL-C. The company has license and collaboration agreements with Daiichi Sankyo Co. Ltd to; Otsuka Pharmaceutical Co., Ltd; and Daiichi Sankyo Europe GmbH. Esperion Therapeutics, Inc. was incorporated in 2008 and is headquartered in Ann Arbor, Michigan.

---

Keywords: Pharmaceutical Cholesterol Hypercholesterolemia Hyperlipidemia Low Density Lipoprotein Familial Hypercholesterolemia Lipid Metabolism Disorders Esperion Therapeutics Heterozygous Familial Hypercholesterolemia Statins

---

Home Page: www.esperion.com

3891 Ranchero Drive
Ann Arbor, MI 48108
United States
Phone: 734 887 3903

---

Officers

Exchange: F

Country: DE : Germany

Currency: Euro (€)